Navigation Links
Data From Phase II Trial of Prolor Biotech's Long-acting Human Growth Hormone Presented at Endo 2012
Date:6/26/2012

t forward-looking statements involve risks and uncertainties that may affect PROLOR's business and prospects, including the risks that PROLOR may not succeed in generating any revenues or developing any commercial products, including any long-acting versions of human growth hormone, erythropoietin, interferon beta, GLP-1 and other products; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from Israel's Office of the Chief Scientist is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in PROLOR's filings with the Securities and Exchange Commission.  The for
'/>"/>
SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Penn researchers study of phase change materials could lead to better computer memory
2. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
3. BioPharm Systems Launches Services to Help Phase I Clinics Implement Oracle Health Sciences LabPas
4. Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine
5. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
6. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
7. Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis
8. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
9. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
10. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
11. Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... GLOBAL MARKETS , that the global market RNA interference ... nearly $38.8 billion by 2018, with a five-year compound ... category, the fastest moving segment of the market, is ... of RNAi therapeutics has shown tremendous growth and has ...
(Date:8/1/2014)... Aug. 1, 2014 Glencoe Software, ... of "Data InPress" ( http://glencoesoftware.com/data-inpress.html ), a ... multidimensional image data into on-line publications.  The ... Video Injection Service. Photo - ... http://photos.prnewswire.com/prnh/20140731/132409 The DataViewer ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Food ... are increasingly searching for food alternatives that offer ... benefits. The food ingredient market has numerous players ... such as Vital Force Technology (VFT). VFT ... than 4,000 energetic patterns, all tested to produce ...
(Date:7/31/2014)... , the leading life sciences employment and news website, launched the ... Illinois , Indiana , ... , Minnesota , Missouri , ... Wisconsin . BioMidwest is a leader in biotech and ... in this region in 2013. The life sciences sector in this area ...
Breaking Biology Technology:Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 3Glencoe Software Launches Data InPress 2Glencoe Software Launches Data InPress 3Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2Midwest Biotech Leaders Featured On BioSpace Map 2
... To validate any RNAi experiment, target mRNA , ... using a positive control siRNA that is known to be effective, , ... , Validation is also necessary ... effectiveness and potency of any siRNA sequence. Finally, , ...
... Microarrays , ... engineered to maximize yields of full-length cDNA , ... 100 ng of input RNA in a single round for GeneChip , ... cRNA synthesis powered by , MEGAscript, the best ...
... Total RNA Isolation from Formalin Fixed Paraffin Embedded (FFPE) Tissues , ... Phenol-free isolation of total RNA from , FFPE tissues , ... href="http://www.ambiondx.com/products/optimum/index.html">Optimum , ... and rapid protocol , for ...
Cached Biology Technology:Confirming RNAi Effects Is Now Easier Than Ever 2Confirming RNAi Effects Is Now Easier Than Ever 3Confirming RNAi Effects Is Now Easier Than Ever 4Confirming RNAi Effects Is Now Easier Than Ever 5Improving RNA Amplification 2Improving RNA Amplification 3Improving RNA Amplification 4Improving RNA Amplification 5Improving RNA Amplification 6Improving RNA Amplification 7Improving RNA Amplification 8Improving RNA Amplification 9Improving RNA Amplification 10Improving RNA Amplification 11Improving RNA Amplification 12Improving RNA Amplification 13Improving RNA Amplification 14Optimum FFPE RNA Isolation Kit 2Optimum FFPE RNA Isolation Kit 3Optimum FFPE RNA Isolation Kit 4
(Date:7/31/2014)... protected 100 percent of animal models against the highly ... causes an intestinal disease that kills approximately 30,000 Americans ... Infection and Immunity . , In the ... against the purified toxins produced by C. difficile ... a laboratory model that mimics the human disease, after ...
(Date:7/31/2014)... better identify and treat those with fibromuscular dysplasia (FMD). ... sized arteries in the body, which can restrict blood flow ... new report appearing in August 2014 issue of ... FMD may not be limited to the arteries as currently ... bones and joints, as well as evidence that inflammation may ...
(Date:7/31/2014)... they are an iconic symbol of tropical resorts ... landscape. Some, like Hawaii,s State Flower- Hibiscus ... relatively few botanists and Hawaiian conservation workers, however, ... related group of plants known as Hibiscadelphus ... Hibiscus species are in fact highly endangered. Until ...
Breaking Biology News(10 mins):C. difficile vaccine proves safe, 100 percent effective in animal models 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2Brother of Hibiscus is found alive and well on Maui 2
... developed a slow-release anesthetic drug-delivery system that could ... surgery, and may also have a large impact ... used specially designed fat-based particles called liposomes to ... local anesthesia in rats without apparent toxicity to ...
... Climate change will cause some of Australia,s potential weeds to ... by scientists at CSIRO,s Climate Adaptation Flagship. Weeds cost ... or lost production and cause serious damage to the environment. ... GREENHOUSE 09 conference on climate change, CSIRO researcher, Dr John ...
... Fast food and soft drinks may be making children fatter ... tackling childhood obesity, by reducing children,s consumption of unhealthy food ... also actively seek to keep children happy in other ways, ... Professor Rodolfo Nayga from the University of Arkansas in the ...
Cached Biology News:Long-lasting nerve block could change pain management 2Climate change may wake up 'sleeper' weeds 2Eat, drink and be merry? 2
Ready for formulation or direct injection into animals Provided in convenient 100, 250, 1000 and 10,000 nmol sizes HPLC purified, salt free, sterile filtered, and endotoxin tested ...
... the premium quality siRNAs you need for ... be readily ordered online by providing either ... providing the sense and antisense siRNA sequences. ... Validated and Silencer Pre-designed siRNAs, ...
GEL FILTRATION CAL KIT HMW, 1 EA. *Category: Gel Filtration Gels....
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Biology Products: